Registry-based randomised phase II study of Enzalutamide versus Abiraterone: assessing cognitive function in eLderly patients with metastatic castration-resistant Prostate cancer (REAL-Pro).
무작위 임상시험
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: metastatic castration-resistant prostate cancer (mCRPC)
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
There were no differences in TTF, OS, prostate-specific antigen response, or AE rates between treatment groups. [CONCLUSIONS] Our results highlight the importance of individualised assessment of cognition, depression, and falls risk in older patients commencing ARPI treatment.
[BACKGROUND] Androgen receptor pathway inhibitors (ARPIs) are commonly used in older patients with metastatic castration-resistant prostate cancer (mCRPC).
- 95% CI 1.09-1.22
APA
Anton A, Steer C, et al. (2026). Registry-based randomised phase II study of Enzalutamide versus Abiraterone: assessing cognitive function in eLderly patients with metastatic castration-resistant Prostate cancer (REAL-Pro).. ESMO real world data and digital oncology, 11, 100677. https://doi.org/10.1016/j.esmorw.2025.100677
MLA
Anton A, et al.. "Registry-based randomised phase II study of Enzalutamide versus Abiraterone: assessing cognitive function in eLderly patients with metastatic castration-resistant Prostate cancer (REAL-Pro).." ESMO real world data and digital oncology, vol. 11, 2026, pp. 100677.
PMID
41757352 ↗
Abstract 한글 요약
[BACKGROUND] Androgen receptor pathway inhibitors (ARPIs) are commonly used in older patients with metastatic castration-resistant prostate cancer (mCRPC). Treatment selection is informed by considering adverse event (AE) profiles, given that there are no previous randomised phase III comparison trials.
[MATERIALS AND METHODS] This prospective registry-based randomised trial utilised the electronic Prostate Cancer Australian Database to collect clinical data. Patients aged ≥75 years who were suitable to receive abiraterone or enzalutamide for mCRPC were randomised to receive either ARPI treatment, stratified by prior docetaxel use. Telephone assessments were conducted at baseline and 12 weeks, including the Blessed Orientation-Memory-Concentration (BOMC) tool, Geriatric Depression Scale (GDS), and Falls Risk Questionnaire (FRQ). Descriptive statistics and mixed-effects linear regression were used to compare groups, including changes in assessment scores from baseline. Cox proportional hazards modelling was used to analyse effects of variables on time to treatment failure (TTF) and overall survival (OS).
[RESULTS] We enrolled 76 men between June 2019 and September 2023, but closed due to slow accrual in December 2023. Nineteen (25%) had prior docetaxel. The median age was 81 years (interquartile range 77-85 years). The mean score change at 12 weeks trended higher in those receiving enzalutamide for each of BOMC (+0.64 versus -0.51, = 0.46), GDS (+0.70 versus +0.06, = 0.06), and FRQ (+1.4 versus -0.12, = 0.06). A higher baseline GDS score was associated with shorter TTF [hazard ratio (HR) 1.3, 95% confidence interval (CI) 1.05-1.6, = 0.014], as was higher baseline FRQ score (HR 1.12, 95% CI 1.09-1.22, = 0.012). There were no differences in TTF, OS, prostate-specific antigen response, or AE rates between treatment groups.
[CONCLUSIONS] Our results highlight the importance of individualised assessment of cognition, depression, and falls risk in older patients commencing ARPI treatment.
[MATERIALS AND METHODS] This prospective registry-based randomised trial utilised the electronic Prostate Cancer Australian Database to collect clinical data. Patients aged ≥75 years who were suitable to receive abiraterone or enzalutamide for mCRPC were randomised to receive either ARPI treatment, stratified by prior docetaxel use. Telephone assessments were conducted at baseline and 12 weeks, including the Blessed Orientation-Memory-Concentration (BOMC) tool, Geriatric Depression Scale (GDS), and Falls Risk Questionnaire (FRQ). Descriptive statistics and mixed-effects linear regression were used to compare groups, including changes in assessment scores from baseline. Cox proportional hazards modelling was used to analyse effects of variables on time to treatment failure (TTF) and overall survival (OS).
[RESULTS] We enrolled 76 men between June 2019 and September 2023, but closed due to slow accrual in December 2023. Nineteen (25%) had prior docetaxel. The median age was 81 years (interquartile range 77-85 years). The mean score change at 12 weeks trended higher in those receiving enzalutamide for each of BOMC (+0.64 versus -0.51, = 0.46), GDS (+0.70 versus +0.06, = 0.06), and FRQ (+1.4 versus -0.12, = 0.06). A higher baseline GDS score was associated with shorter TTF [hazard ratio (HR) 1.3, 95% confidence interval (CI) 1.05-1.6, = 0.014], as was higher baseline FRQ score (HR 1.12, 95% CI 1.09-1.22, = 0.012). There were no differences in TTF, OS, prostate-specific antigen response, or AE rates between treatment groups.
[CONCLUSIONS] Our results highlight the importance of individualised assessment of cognition, depression, and falls risk in older patients commencing ARPI treatment.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Prostate Cancer Care for Men with an Intellectual Disability: A Population-based Cohort Study of Symptoms, Diagnosis, Treatment, and Survival.
- Association between polygenic risk scores and cardiovascular events in prostate cancer patients receiving androgen deprivation therapy in Han Chinese.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Interleukin-11: A pivotal player and potential therapeutic target in prostate cancer.
- DIAPH3 is a multifaceted prognostic biomarker that links immunotherapy response to tumor microenvironment in prostate cancer.
- Machine learning approaches to optimize the integration of sociodemographic factors for predicting cancer-specific survival among patients with high-risk prostate cancer.